z-logo
open-access-imgOpen Access
Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma
Author(s) -
Bert H. O’Neil,
Laura W. Goff,
John S. Kauh,
Jonathan Strosberg,
Tanios BekaiiSaab,
Ruey-min Lee,
Aslamuzzaman Kazi,
Dominic T. Moore,
Maria Learoyd,
Richard M. Lush,
Saı̈d M. Sebti,
Daniel M. Sullivan
Publication year - 2011
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/d1bm-nh04
Subject(s) - selumetinib , hepatocellular carcinoma , protein kinase a , mek inhibitor , cancer research , medicine , mapk/erk pathway , mitogen activated protein kinase kinase , oncology , kinase , chemistry , biochemistry

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom